Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4954673 | 1.00 | ALDH1A1 (0.39) | ALDH1A1FKBP5CRBNKDM4EGAA | |
| SCHEMBL30545269 | 1.00 | ALDH1A1 (0.39) | ALDH1A1FKBP5CRBNKDM4EGAA | |
| SCHEMBL29636334 | 1.00 | ALDH1A1 (0.39) | ALDH1A1FKBP5CRBNKDM4EGAA | |
| SCHEMBL4954670 | 1.00 | ALDH1A1 (0.39) | ALDH1A1FKBP5CRBNKDM4EGAA | |
| SCHEMBL541181 | 0.98 | — | — | |
| SCHEMBL541182 | 0.98 | — | — | |
| SCHEMBL651905 | 0.91 | — | — | |
| 5,6-Dihydro-2(1H)-Pyridinone SCHEMBL49488 | 0.80 | — | — | |
| 5,6-Dihydro-2(1H)-Pyridinone SCHEMBL9464948 | 0.78 | — | — | |
| 5,6-Dihydro-2(1H)-Pyridinone SCHEMBL31482438 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648858-B1 | METHOD FOR PRODUCTION OF ALPHA, BETA-UNSATURATED AMIDE COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20060281949-A1 | Method for production $g(a),$g(b)-unsaturated amide compounds | SIEGFRIED GENERICS INTERNATIONAL AG (CH) | 2006-12-14 | — | — | US | disclosed |
| EP-1648858-A1 | METHOD FOR PRODUCTION OF ALPHA, BETA-UNSATURATED AMIDE COMPOUNDS | Siegfried Generics International AG (CH) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005007618-A1 | METHOD FOR PRODUCTION OF $G(A),$G(B)-UNSATURATED AMIDE COMPOUNDS | SIEGFRIED GENERICS INTERNATIONAL AG (CH) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281949-A1 | Method for production $g(a),$g(b)-unsaturated amide compounds | GSTA2, GSTO1, GLB1 | ALDH1A1 218/4885FKBP5 1590/4885CRBN 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.